BACKGROUND: Vascular endothelial growth factor (VEGF) is one of the angiogenic mediators that can be secreted by leukemic cells and plays an important role in tumor invasion and metastasis. Another important agent contributing to the relapse of ALL is C-X-C chemokine receptor type-4 (CXCR-4), expression of this receptor in cancer cells has been related to metastasis. It has been identified that genistein-a soy-derived isoflavonoid-has anti-angiogenesis functions. We aimed to show the effects of this compound on VEGF and CXCR-4 in Acute lymphoblastic leukemia (ALL) cell models. METHODS AND RESULTS: The cytotoxicity of Genistein was measured using the MTS colorimetric assay. After being treated with Genistein, the expression of VEGF in mRNA and protein levels was measured in MOLT-4 and Jurkat cells. We also used flow cytometry assay to determine the expression of CXCR-4 in cell surfaces. We found that Genistein decreased cell viability in two cell models while was more effective on MOLT-4 cells. After Genistein-treatment, surface expression levels of CXCR-4 were decreased, while VEGF secretion and mRNA expression levels were increased in MOLT-4 and Jurkat cells. CONCLUSIONS: The results suggest that Genistein may not be a reliable choice for the treatment of ALL; however, this different identified pattern can be useful for the recognition of VEGF and CXCR-4 modulators and thus for planning new treatments for leukemia and other VEGF related disorders.
BACKGROUND: Vascular endothelial growth factor (VEGF) is one of the angiogenic mediators that can be secreted by leukemic cells and plays an important role in tumor invasion and metastasis. Another important agent contributing to the relapse of ALL is C-X-C chemokine receptor type-4 (CXCR-4), expression of this receptor in cancer cells has been related to metastasis. It has been identified that genistein-a soy-derived isoflavonoid-has anti-angiogenesis functions. We aimed to show the effects of this compound on VEGF and CXCR-4 in Acute lymphoblastic leukemia (ALL) cell models. METHODS AND RESULTS: The cytotoxicity of Genistein was measured using the MTS colorimetric assay. After being treated with Genistein, the expression of VEGF in mRNA and protein levels was measured in MOLT-4 and Jurkat cells. We also used flow cytometry assay to determine the expression of CXCR-4 in cell surfaces. We found that Genistein decreased cell viability in two cell models while was more effective on MOLT-4 cells. After Genistein-treatment, surface expression levels of CXCR-4 were decreased, while VEGF secretion and mRNA expression levels were increased in MOLT-4 and Jurkat cells. CONCLUSIONS: The results suggest that Genistein may not be a reliable choice for the treatment of ALL; however, this different identified pattern can be useful for the recognition of VEGF and CXCR-4 modulators and thus for planning new treatments for leukemia and other VEGF related disorders.
Authors: M Masiero; S Minuzzo; I Pusceddu; L Moserle; L Persano; V Agnusdei; V Tosello; G Basso; A Amadori; S Indraccolo Journal: Leukemia Date: 2011-01-25 Impact factor: 11.528
Authors: Vera Münch; Luca Trentin; Julia Herzig; Salih Demir; Felix Seyfried; Johann M Kraus; Hans A Kestler; Rolf Köhler; Thomas F E Barth; Geertruy Te Kronnie; Klaus-Michael Debatin; Lüder H Meyer Journal: Blood Date: 2017-05-26 Impact factor: 22.113
Authors: Caroline Demacq; Vivian B Vasconcellos; Tatiane C Izidoro-Toledo; Vanessa da Silva Silveira; Renata Canalle; Rosane Gomes de Paula Queiroz; Luiz Gonzaga Tone; Jose E Tanus-Santos Journal: Clin Chim Acta Date: 2010-05-25 Impact factor: 3.786
Authors: P Mirshahi; A Rafii; L Vincent; A Berthaut; R Varin; G Kalantar; C Marzac; O A Calandini; J-P Marie; C Soria; J Soria; M Mirshahi Journal: Leukemia Date: 2009-04-02 Impact factor: 11.528